XML 57 R44.htm IDEA: XBRL DOCUMENT v3.25.3
Schedule of Contractual Clinical Trials (Details)
9 Months Ended
Sep. 30, 2025
USD ($)
Integer
Other Commitments [Line Items]  
Remaining financial contractual commitment $ 292,000
Phase 1b 2 [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2)
Estimated Start Date January 2024
Estimated End Date December 2027
Number of Patients in Trial | Integer 21
Expected Date December 2026
Remaining financial contractual commitment $ 0 [1]
Phase 1b [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with atezolizumab in microsatellite stable metastatic colorectal cancer (Phase 1b)
Estimated Start Date August 2024
Estimated End Date December 2026
Number of Patients in Trial | Integer 37
Expected Date June 2026
Remaining financial contractual commitment $ 0 [1]
Phase 1b Two [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b)
Estimated Start Date June 2023
Number of Patients in Trial | Integer 14
Expected Date December 2025
Remaining financial contractual commitment $ 292,000
[1] The Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.